Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference - Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO® (nivolumab) -- Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for...